$36.71
0.90% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$37.04
-1.51 3.92% 1M
+10.54 39.77% 6M
+3.74 11.23% YTD
+13.70 58.70% 1Y
+13.88 59.93% 3Y
+20.39 122.46% 5Y
+34.38 1,292.48% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.65 1.79%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Market capitalization $10.37b
Enterprise Value $9.47b
P/E (TTM) P/E ratio 20.90
EV/FCF (TTM) EV/FCF 14.10
EV/Sales (TTM) EV/Sales 4.37
P/S ratio (TTM) P/S ratio 4.78
P/B ratio (TTM) P/B ratio 4.65
Revenue growth (TTM) Revenue growth 18.49%
Revenue (TTM) Revenue $2.17b
EBIT (operating result TTM) EBIT $689.95m
Free Cash Flow (TTM) Free Cash Flow $671.54m
Cash position $1.11b
EPS (TTM) EPS $1.77
P/E forward 18.21
P/S forward 4.61
EV/Sales forward 4.21
Short interest 6.38%
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Exelixis, Inc. forecast:

11x Buy
50%
10x Hold
45%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Exelixis, Inc. forecast:

Buy
50%
Hold
45%
Sell
5%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,169 2,169
18% 18%
100%
- Direct Costs 76 76
5% 5%
4%
2,092 2,092
19% 19%
96%
- Selling and Administrative Expenses 463 463
8% 8%
21%
- Research and Development Expense 910 910
13% 13%
42%
719 719
241% 241%
33%
- Depreciation and Amortization 29 29
27% 27%
1%
EBIT (Operating Income) EBIT 690 690
304% 304%
32%
Net Profit 521 521
151% 151%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Positive
The Motley Fool
about 7 hours ago
One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices, it's possible to buy shares of quality stocks with $50 -- or less.
Neutral
Business Wire
8 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) adult and p...
Neutral
Business Wire
9 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL. “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the...
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today